NASDAQ:ARDXArdelyx Stock Price, Forecast & News

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARDX shares have decreased by 6.2% and is now trading at $5.61.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ardelyx.

Ardelyx is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Ardelyx.

Ardelyx Inc (NASDAQ:ARDX) announced its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.01. Ardelyx had a negative net margin of 1,090.69% and a negative return on equity of 65.94%.
View Ardelyx's earnings history.

5 analysts have issued 12-month price objectives for Ardelyx's shares. Their forecasts range from $9.00 to $15.00. On average, they expect Ardelyx's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 113.9% from the stock's current price.
View analysts' price targets for Ardelyx.

News articles about ARDX stock have been trending somewhat negative on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ardelyx earned a news impact score of -1.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Ardelyx.

Ardelyx saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 5,440,000 shares, an increase of 68.9% from the June 15th total of 3,220,000 shares. Based on an average daily trading volume, of 769,100 shares, the days-to-cover ratio is presently 7.1 days.
View Ardelyx's Short Interest.

Some companies that are related to Ardelyx include Prestige Consumer Healthcare (PBH), Xencor (XNCR), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Intercept Pharmaceuticals (ICPT), IGM Biosciences (IGMS), I-Mab (IMAB), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Revance Therapeutics (RVNC), Ironwood Pharmaceuticals (IRWD), Y-mAbs Therapeutics (YMAB), Corcept Therapeutics (CORT) and INDIVIOR PLC/S (INVVY).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), Novavax (NVAX), SCYNEXIS (SCYX) and Advanced Micro Devices (AMD).

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (15.33%), Vanguard Group Inc. (4.05%), Marshall Wace LLP (3.71%), Ikarian Capital LLC (1.56%), Goldman Sachs Group Inc. (0.74%) and Bailard Inc. (0.52%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Mark Kaufmann, Michael Raab and Scott D Sandell.
View institutional ownership trends for Ardelyx.

ARDX stock was sold by a variety of institutional investors in the last quarter, including NEA Management Company LLC, EAM Investors LLC, FMR LLC, Ikarian Capital LLC, Goldman Sachs Group Inc., Bailard Inc., Marshall Wace LLP, and Strs Ohio. Company insiders that have sold Ardelyx company stock in the last year include Elizabeth A Grammer, Forest Baskett, Mark Kaufmann, Michael Raab, and Scott D Sandell.
View insider buying and selling activity for Ardelyx.

ARDX stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Teacher Retirement System of Texas, Swiss National Bank, Alps Advisors Inc., Hamilton Lane Advisors LLC, Principal Financial Group Inc., California Public Employees Retirement System, and Bank of New York Mellon Corp.
View insider buying and selling activity for Ardelyx.

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARDX stock can currently be purchased for approximately $5.61.

Ardelyx has a market capitalization of $500.08 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 88 workers across the globe.

The official website for Ardelyx is www.ardelyx.com.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]